Lipid nanoparticles for mRNA delivery

Moderna Therapeutics, Pfizer, Sanofi S.A., BioNTech AG and Acuitas Therapeutics are among the companies working on mRNA-LNPs. Their activities include vaccines, therapeutic programs and delivery-platform development. The field also includes patent activity from organizations such as Curevac Inc. and Intellia Therapeutics. These examples span both product development and underlying delivery technology.

The listed startups include Acuitas Therapeutics, Recode Therapeutics and Etherna Immunotherapies. Acuitas develops LNP delivery technology for molecular therapeutics, while Recode focuses on LNP medicines for genetic respiratory diseases. Etherna develops mRNA immunotherapies using LNP delivery. The available information describes their programs but does not provide comparative evidence to rank their prospects.

The University of Pennsylvania leads the listed organizations with 328 documents in the 24-month window, followed by the Chinese Academy of Sciences CAS with 137 and Zhejiang University with 95. Other active research organizations include Peking University and the Massachusetts Institute of Technology. Recent work spans organ targeting, lipid chemistry, formulation and therapeutic applications.

Funding data lists $90,507,731 in grants across 68 grants since 2020. These figures describe funding associated with the topic data, not a verified total for LNP-mRNA programs alone. The available information does not break down the grant amounts by specific application, organization or delivery approach.

Modernatx Inc. leads the listed patent holders with 51 patents, followed by Curevac Inc. with 30 and Intellia Therapeutics with 24. BioNTech AG is listed with 22, while Shenzhen Shenxin Biotechnology Co. has 18. These figures describe patent counts in the available holder data.

Patent activity declined 52.7% in the last 12 months compared with the previous 12 months, while the 24-month window contains 1,184 patents. This contrasts with publication growth: publications in the last year increased 45.0%. The figures point to different recent directions in patenting and research output, rather than a uniform change across all activity.

Recent work includes lung-selective delivery reported by Nanjing University and collaborators in August 2026, and a study of NAD⁺-augmented LNPs from Jilin University and collaborators that month. September 2026 publications explored prophylactic mRNA-LNP vaccination for breast cancer and antibody-modified LNPs for HER2-expressing cancer cells. These studies target delivery specificity and therapeutic response.

The five listed approaches are ionizable lipid chemistry, biodegradable lipids, organ-targeted formulations, ligand-mediated targeting, and formulation and assembly. They address different design problems: lipid structure and breakdown, tissue distribution, cell binding, and particle production. Their trade-offs include balancing delivery performance with safety, stability, reproducibility and manufacturing complexity.

The listed applications include infectious disease vaccines, cancer immunotherapy, gene editing and cell engineering, protein replacement, and allergy and immune disorders. Cancer immunotherapy has 1,003 documents and 55.2% recent growth; infectious disease vaccines have 1,519 documents. The figures reflect recorded research activity, not a comparison of clinical effectiveness.

The United States leads with 8,468 documents, followed by China with 2,799 and the United Kingdom with 2,307. Germany is listed with 2,153 documents, and Canada with 1,109. The data shows activity across research and industry, but document counts alone do not measure product readiness or clinical impact.